Life saving therapy denied to dying cop

20 November 2019 - Doctors at Sydney’s Royal Prince Alfred Hospital are refusing to treat a terminally ill cancer ­patient ...

Read more →

Medexus granted priority review status for Gliolan by Health Canada

19 November 2019 - Medexus Pharmaceuticals today announced that Health Canada has granted priority review status for the new drug ...

Read more →

Genmab announces European marketing authorization for Darzalex (daratumumab) in combination with lenalidomide and dexamethasone in frontline multiple myeloma

19 November 2019 - Approval based on data from Phase III MAIA study. ...

Read more →

Game changing cancer medicines now within reach for 2,200 Australians

20 November 2019 - Australians living with non-small cell lung cancer and early stage acute lymphoblastic leukaemia will be able to ...

Read more →

Lung cancer and leukaemia treatments to be added to PBS

19 November 2019 - “Game changing” drugs for types of lung cancer and leukaemia will be added to the Pharmaceutical Benefits ...

Read more →

CHMP recommends EU approval of Roche’s Kadcyla for the adjuvant treatment of people with HER2-positive early breast cancer with residual invasive disease after neo-adjuvant treatment

15 November 2019 - Kadcyla cut the risk of disease recurrence or death by half compared to Herceptin in the adjuvant ...

Read more →

CHMP recommends conditional EU approval of Roche’s Polivy for people with previously treated aggressive lymphoma

15 November 2019 - First-in-class antibody-drug conjugate that specifically targets CD79b, a protein expressed in the majority of B-cells. ...

Read more →

FDA approves therapy to treat patients with relapsed and refractory mantle cell lymphoma supported by clinical trial results showing high response rate of tumour shrinkage

14 November 2019 - Today, the U.S. FDA granted accelerated approval to Brukinsa (zanubrutinib) capsules for the treatment of adult patients ...

Read more →

Clovis Oncology announces reimbursement for Rubraca (rucaparib) tablets for women with relapsed ovarian cancer in Italy

13 November 2019 - Rucaparib now reimbursed in several countries in Europe with additional countries to follow in 2020. ...

Read more →

FDA’s Project Orbis may expand to Singapore and Switzerland

12 November 2019 - The US FDA may expand a pilot project that allows for simultaneous drug approval decisions from ...

Read more →

Viracta receives fast track designation for nanatinostat combination for the treatment of EBV-associated lymphomas

12 November 2019 - Viracta Therapeutic, announced today that the U.S. FDA has granted fast track designation for nanatinostat in ...

Read more →

Exelixis’ partner Ipsen announces Health Canada’s approval of Cabometyx (cabozantinib) tablets for the treatment of patients with previously treated advanced hepatocellular carcinoma

12 November 2019 - Approval based on statistically significant and clinically meaningful overall survival benefit demonstrated in the CELESTIAL phase 3 ...

Read more →

Health economic assessment of Tecentriq for triple negative breast cancer

8 November 2019 - TLV has produced a health economic knowledge base for the county council for the drug Tecentriq (atezolizumab).  ...

Read more →

'Incredibly upsetting': breast cancer patients dealing with shortage of common drug treatment

12 November 2019 - When Tricia Smith tried to fill her prescription for tamoxifen two weeks ago, she was shocked ...

Read more →

Lung cancer ALK+NSCLC genetic mutation screening could save lives - doctors

12 November 2019 - Lives are being needlessly cut short because there's no universal testing for a type of lung ...

Read more →